Evaluation of acute, long term, or repeated drug treatment toxicity using OncoCilAir™

Accurate evaluation of the potential side-toxicity of a new treatment is a critical step in drug development. OncoCilAir™ allows for translational testing of drug toxicity directly in human tissue.

Because of its dual component, a healthy airway epithelium combined with tumour nodules, OncoCilair™ is ideal to test simultaneously the effectiveness and THE TOXICITY of anticancer drugs.

OncoCilAir™: a functional lung cancer model cultured at the air-liquid interface.

Apical or basolateral exposures studies can be run to mimic airborne or systemic delivery respectively. For apical exposure, compounds can be applied by nebulisation, using the Vitrocell-Cloud, a system specially designed for dose-controlled and spatially uniform deposition of liquid aerosols on cells cultured at the air-liquid interface.

x

Vitrocell-Cloud exposure system and principle

Endpoints commonly used for toxicity evaluation

• Morphological modifications: Apical pictures recording (qualitative)
• Tissue integrity monitoring: TEER measurement (quantitative)
• Cytotoxicity monitoring: LDH Release (quantitative)
• Cilia beating monitoring: Evaluation of cilia beating frequency (quantitative)
• Histological markers: Caspase-3,-6,-7 ; Anexin V (qualitative and quantitative)

Evaluation of anticancer drugs toxicity on OncoCilAir airway epithelium integrity by Trans-Epithelial Electrical Resistance (TEER) monitoring during 20 days (• Control, ■ docetaxel, ∆ selumetinib,▼trametinib).